Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CDW Holding ( (SG:BXE) ) just unveiled an update.
CDW Holding Limited’s subsidiary, ABio, in collaboration with Neoregen Biotech Co., Ltd., is advancing its research on next-generation Lipid Nanoparticle (LNP) technology. Following promising results from the in vitro phase, the joint research is set to enter the in vivo phase in April 2025, marking a significant step towards developing more effective and safer drug delivery systems. This progression is expected to enhance CDW’s position in the biotechnology industry, potentially benefiting stakeholders by expanding applications in mRNA vaccines, cancer treatment, and gene therapy.
More about CDW Holding
CDW Holding Limited is a company listed on the SGX Mainboard, operating in the biotechnology sector through its subsidiary A Biotech Co., Limited (ABio). The company focuses on the development of innovative technologies such as Lipid Nanoparticle (LNP) technology, which is crucial for drug delivery systems, mRNA vaccines, cancer treatment, and gene therapy.
YTD Price Performance: -7.00%
Technical Sentiment Signal: Buy
Current Market Cap: $21.5M
For a thorough assessment of BXE stock, go to TipRanks’ Stock Analysis page.